Structurally Modified Analogues of Glucagon-Like Peptide-1 (GLP-1) and Glucose-Dependent Insulinotropic Polypeptide (GIP) As Future Antidiabetic Agents
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1(7-36)amide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gastrointestinal insulin-releasing hormones involved in the regulation of postprandial nutrient homeostasis. These two incretin hormones are glucose-dependent stimulators of pancreatic beta-cell function, exhibiting a spectrum of secondary extrapancreatic activities, which favour the efficient control of blood glucose homeostasis. Such actions of GLP-1 and GIP have generated considerable interest in their possible exploitation as novel agents for the treatment of type 2 diabetes. Despite the many attributes of GLP-1 and GIP as possible future antidiabetic agents, their rapid degradation in the circulation by dipeptidyl peptidase IV (DPP IV) to inactive truncated forms GLP-1(9-36)amide and GIP(3-42), severely limits their therapeutic usefulness. This review will consider recent developments in the design and effectiveness of synthetic DPP IV-resistant analogues of GLP-1 and GIP. Consideration will be given to the effects of N-terminal modification and amino acid substitution of GLP-1 and GIP either side of the DPP IV cleavage site on (i) susceptibility to enzymatic degradation, (ii) binding to native hormone receptor, (iii) ability to elevate intracellular cyclic AMP, (iv) potency as insulin secretagogues, and (v) antihyperglycaemic activity in type 2 diabetes. It will be shown that structural modification can produce a varied set of biological activities, ranging from more efficacious analogues to those which antagonise the activity of the native hormone. The antidiabetic properties of the best GLP-1 and GIP analogues indeed promise to provide the basis for novel, effective and long-acting drugs for type 2 diabetes therapy. This approach is currently being pursued actively by the pharmaceutical industry.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“their application in T2DM treatment focuses on modified analogues320, 321, 322, 323, 324, 325 or receptor agonists, including the well-known, short-acting exenatide.326, 327, 328”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [320]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 3×
“These recent observations add to a growing body of evidence, which links GIP to fat deposition, obesity and glucose intolerance [54, 98-100].”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 2×
“Furthermore, the ability of both GLP-1 and GIP to stimulate insulin gene transcription and increase pancreatic beta-cell mass [3, 5, 6, 26, 29], may compensate for the dysregulation of insulin secretion synonymous with type 2 diabetes.”
BackgroundMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 1×
“Years of subsequent research have widely confirmed the insulinotropic action of GLP-1 in islets [16, 17], normal and diabetic animals [18-22] and healthy and diabetic human volunteers [23].”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · cited 1×
“Following cloning of the bovine [8], hamster [9], rat [10] and human [11] preproglucagon genes, it was realised that anglerfish GRP-1 was a homologue of GLP-1, encoded in mammalian genes.”
BackgroundTruncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Exon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 1×
“As pointed out, this may be due to other actions of GLP-1 on the betacell, such as inhibition of KATP channels leading to an influx of Ca [115].”
BackgroundDiabetes Mellitus: Theory and Practice.
(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-75-2-330_2 · Cited by 564
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · cited 1×
“Thus GIP receptor deficient (GIPR) mice exhibit glucose intolerance and diminished insulin secretion [116] and they also appear to be resistant to the development of obesity when placed on a high-fat diet [98].”
BackgroundPerfetti, R. (2000) · Endocrinology · doi:10.1210/en.141.12.4600 · Cited by 442
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 3×
“Furthermore, the ability of both GLP-1 and GIP to stimulate insulin gene transcription and increase pancreatic beta-cell mass [3, 5, 6, 26, 29], may compensate for the dysregulation of insulin secretion synonymous with type 2 diabetes.”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 1×
“Unger and Eisentraut coined the term ‘enteroinsular axis’ in 1969 to describe all of the gut factors, which contribute to enhanced insulin secretion following the ingestion of a meal [1].”
BackgroundFehmann, H. C. (1992) · Endocrinology · doi:10.1210/en.130.1.159 · Cited by 337
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Creutzfeldt, W. O. C., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 330
Zhou, J., Wang, X., Pineyro, M. A., & Egan, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Deacon, C. F., Knudsen, L. B., Madsen, K., Wiberg, F. C., Jacobsen, O., & Holst, J. J. (1998) · Diabetologia · doi:10.1007/s001250050903 · Cited by 303
Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem
Lund, P. K., Goodman, R. H., Dee, P. C., & Habener, J. F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.345 · Cited by 295 · cited 1×
“GLP-1 was first described as glucagon-related peptide (GRP) by the cloning of the anglerfish preproglucagon gene [7].”
BackgroundRolin, B., Larsen, M. O., Gotfredsen, C. F., Deacon, C. F., Carr, R. D., Wilken, M., & Knudsen, L. B. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00030.2002 · Cited by 281
Further purification of a polypeptide demonstrating enterogastrone activity
Brown, J. C., Mutt, V., & Pederson, R. A. (1970) · The Journal of Physiology · doi:10.1113/jphysiol.1970.sp009155 · Cited by 276
Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas
Weir, G. C., Mojsov, S., Hendrick, G. K., & Habener, J. F. (1989) · Diabetes · doi:10.2337/diab.38.3.338 · Cited by 275
Gut Peptides: Biochemistry and Physiology
Walsh, J. H., Dockray, G. J., & Mitty, R. D. (1994) · The Endocrinologist · doi:10.1097/00019616-199411000-00012 · Cited by 267
Pederson, R. A., White, H. A., Schlenzig, D., Pauly, R. P., McIntosh, C. H. S., & Demuth, H.-U. (1998) · Diabetes · doi:10.2337/diab.47.8.1253 · Cited by 267
Natural History of β-Cell Dysfunction in NIDDM
Leahy, J. L. (1990) · Diabetes Care · doi:10.2337/diacare.13.9.992 · Cited by 247
Oral Glucose Augmentation of Insulin Secretion
Andersen, D. K., Elahi, D., Brown, J. C., Tobin, J. D., & Andres, R. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109100 · Cited by 240
Trümper, A., Trümper, K., Trusheim, H., Arnold, R., Göke, B., & Hörsch, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.9.0688 · Cited by 238
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Mammalian pancreatic preproglucagon contains three glucagon-related peptides.
Lopez, L. C., Frazier, M. L., Su, C. J., Kumar, A., & Saunders, G. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.18.5485 · Cited by 234
A two-step model for development of non-insulin-dependent diabetes
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Charles, M. A., & Bennett, P. H. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80165-i · Cited by 234
Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide
Komatsu, R., Matsuyama, T., Namba, M., Watanabe, N., Itoh, H., Kono, N., & Tarui, S. (1989) · Diabetes · doi:10.2337/diab.38.7.902 · Cited by 234
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
Hui, H., Wright, C., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 223
Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes
Eckel, R. H., Fujimoto, W. Y., & Brunzell, J. D. (1979) · Diabetes · doi:10.2337/diab.28.12.1141 · Cited by 219
Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate
Kim, J.-G., Baggio, L. L., Bridon, D. P., Castaigne, J.-P., Robitaille, M. F., Jetté, L., Benquet, C., & Drucker, D. J. (2003) · Diabetes · doi:10.2337/diabetes.52.3.751 · Cited by 210
The Insulinotropic Action of Gastric Inhibitory Polypeptide in the Perfused Isolated Rat Pancreas
PEDERSON, R. A., & BROWN, J. C. (1976) · Endocrinology · doi:10.1210/endo-99-3-780 · Cited by 209
Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice
Ahrén, B., Holst, J. J., Mårtensson, H., & Balkan, B. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00600-2 · Cited by 193
Trumper, A., Trumper, K., & Horsch, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1740233 · Cited by 193
Preparation of highly active enterogastrone
Brown, J. C., Pederson, R. A., Jorpes, E., & Mutt, V. (1969) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y69-020 · Cited by 189
Oben, J., Morgan, L., Fletcher, J., & Marks, V. (1991) · Journal of Endocrinology · doi:10.1677/joe.0.1300267 · Cited by 188
Demonstration of the Humoral Agent in Fat Inhibition of Gastric Secretion.
Kosaka, T., & Lim, R. K. S. (1930) · Experimental Biology and Medicine · doi:10.3181/00379727-27-5024 · Cited by 169
Sudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J.-L., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
HEINRICH, G., GROS, P., LUND, P. K., BENTLEY, R. C., & HABENER, J. F. (1984) · Endocrinology · doi:10.1210/endo-115-6-2176 · Cited by 158
Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)
Edvell, A. (1999) · Endocrinology · doi:10.1210/en.140.2.778 · Cited by 154
Potent glycogenic effect of GLP-1(7?36)amide in rat skeletal muscle
Villanueva-Pe�acarrillo, M. L., Alc�ntara, A. I., Clemente, F., Delgado, E., & Valverde, I. (1994) · Diabetologia · doi:10.1007/bf00418382 · Cited by 152
Pospisilik, J. A., Stafford, S. G., Demuth, H., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 146
Microspheres as nasal drug delivery systems
Pereswetoff-Morath, L. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00069-0 · Cited by 145
Deacon, C. F., Danielsen, P., Klarskov, L., Olesen, M., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1588 · Cited by 145
Deacon, C., Wamberg, S., Bie, P., Hughes, T., & Holst, J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 145
Holz, G. G., & Chepurny, O. G. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033456648 · Cited by 144
Hinke, S. A., Gelling, R. W., Pederson, R. A., Manhart, S., Nian, C., Demuth, H., & McIntosh, C. H. S. (2002) · Diabetes · doi:10.2337/diabetes.51.3.652 · Cited by 142
Gault, V. A., O'Harte, F. P. M., Harriott, P., Mooney, M., Green, B., & Flatt, P. R. (2003) · Diabetologia · doi:10.1007/s00125-002-1028-x · Cited by 139
Self-citationGlucagon‐like peptide 1: A potent glycogenic hormone
Valverde, I., Morales, M., Clemente, F., López-Delgado, M. I., Delgado, E., Perea, A., & Villanueva-Peñacarrillo, M. L. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00699-7 · Cited by 135
Nutrient regulation of insulin secretion
Flatt, P. R. (1992) · Medical Entomology and Zoology · Cited by 132
Self-citationβ-Cell Differentiation from a Human Pancreatic Cell Line in Vitro and in Vivo
de la Tour, D. D., Halvorsen, T., Demeterco, C., Tyrberg, B., Itkin‐Ansari, P., Loy, M., Yoo, S.-J., Hao, E., Bossie, S., & Levine, F. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.3.0604 · Cited by 129
Skoglund, G., Hussain, M. A., & Holz, G. G. (2000) · Diabetes · doi:10.2337/diabetes.49.7.1156 · Cited by 127
Knapper, J. M. E., Puddicombe, S. M., Morgan, L., & Fletcher, J. M. (1995) · Journal of Nutrition · doi:10.1093/jn/125.2.183 · Cited by 126
Bailey, C. J., Flatt, P. R., Kwasowski, P., Powell, C. J., & Marks, V. (1986) · Acta Endocrinologica · doi:10.1530/acta.0.1120224 · Cited by 116
Self-citationScrocchi, L. A., Marshall, B. A., Cook, S. M., Brubaker, P. L., & Drucker, D. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.632 · Cited by 114
Qualmann, C., Nauck, M. A., Holst, J. J., �rskov, C., & Creutzfeldt, W. (1995) · Acta Diabetologica · doi:10.1007/bf00581038 · Cited by 111
Burcelin, R., Dolci, W., & Thorens, B. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90043-4 · Cited by 107
Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?
Gault, V. A., O'Harte, F. P. M., & Flatt, P. R. (2003) · Neuropeptides · doi:10.1016/j.npep.2003.09.002 · Cited by 107
Self-citationBiological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo
Xiao, Q., Giguere, J., Parisien, M., Jeng, W., St-Pierre, S. A., Brubaker, P. L., & Wheeler, M. B. (2001) · Biochemistry · doi:10.1021/bi0014498 · Cited by 106
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6364 · Cited by 104
Self-citationPauly, R. P., Demuth, H., Rosche, F., Schmidt, J., White, H. A., Lynn, F. C., McIntosh, C. H. S., & Pederson, R. A. (1999) · Metabolism · doi:10.1016/s0026-0495(99)90090-2 · Cited by 102
Abnormalities of GIP in Spontaneous Syndromes of Obesity and Diabetes in Mice
Flatt, P. R., Bailey, C. J., Kwasowski, P., Swanston-Flatt, S. K., & Marks, V. (1983) · Diabetes · doi:10.2337/diab.32.5.433 · Cited by 101
Self-citationGault, V. A., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01361-5 · Cited by 99
Self-citationPotential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet
Gutniak, M. K., Larsson, H., Heiber, S. J., Juneskans, O. T., Holst, J. J., & Ahrén, B. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.843 · Cited by 99
Göke, R., Wagner, B., Fehmann, H. C., & Göke, B. (1993) · Research in Experimental Medicine · doi:10.1007/bf02576216 · Cited by 96
Ribel, U., Larsen, M. O., Rolin, B., Carr, R. D., Wilken, M., Sturis, J., Westergaard, L., Deacon, C. F., & Knudsen, L. B. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02189-1 · Cited by 84
Wang, Y., Montrose‐Rafizadeh, C., Adams, L. G., Raygada, M. J., Nadiv, O., & Egan, J. M. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03701-2 · Cited by 84
GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions
Gutniak, M., Larsson, H., Sanders, S. W., Juneskans, O. T., Holst, J. J., & Åhrén, B. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1874 · Cited by 84
Critchley, H., Davis, S. S., Farraj, N. F., & Illum, L. (1994) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1994.tb03876.x · Cited by 82
O'Harte, F. P. M., Gault, V. A., Parker, J. C., Harriott, P., Mooney, M. H., Bailey, C. J., & Flatt, P. R. (2002) · Diabetologia · doi:10.1007/s00125-002-0894-6 · Cited by 73
Self-citationRenal catabolism of human glucagon-like peptides 1 and 2
Ruiz-Grande, C., Pintado, J., Alarcón, C., Castilla, C., Valverde, I., & López-Novoa, J. M. (1990) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y90-239 · Cited by 72
A synthetic glucagon-like peptide-1 analog with improved plasma stability
Ritzel, U., Leonhardt, U., Ottleben, M., Rühmann, A., Eckart, K., Spiess, J., & Ramadori, G. P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590093 · Cited by 69
GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro
Gallwitz, B., Ropeter, T., Morys‐Wortmann, C., Mentlein, R., Siegel, E. G., & Schmidt, W. E. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00095-6 · Cited by 68
O'Harte, F. P., Mooney, M. H., & Flatt, P. R. (1999) · Diabetes · doi:10.2337/diabetes.48.4.758 · Cited by 68
Self-citationGreen, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800379 · Cited by 57
Self-citationEffect of Glucagon-Like Peptide-1 on Gastric Somatostatin and Gastrin Secretion in the Rat
Eissele, R., Koop, H., & Arnold, R. (1990) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529009095514 · Cited by 55
Characterization of GIP(1–30) and GIP(1–42) as stimulators of proinsulin gene transcription
Fehmann, H. C., & Göke, B. (1995) · Peptides · doi:10.1016/0196-9781(95)00090-7 · Cited by 50
O'Harte, F. P. M., Mooney, M., Kelly, C. M., & Flatt, P. R. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650639 · Cited by 50
Self-citationInhalation delivery of proteins from ethanol suspensions
Choi, W. S., Murthy, G. G. K., Edwards, D. A., Langer, R., & Klibanov, A. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201413798 · Cited by 49
Joseph, J. W., Kalitsky, J., St-Pierre, S. A., & Brubaker, P. L. (2000) · Diabetologia · doi:10.1007/s001250051529 · Cited by 47
O'Harte, F. P. M., Mooney, M. H., Lawlor, A., & Flatt, P. R. (2000) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00214-7 · Cited by 47
Self-citationBaggio, L. L., Adatia, F. A., Bock, T. G., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 46
Green, B. D., Gault, V. A., Mooney, M. H., Irwin, N., Harriott, P., Greer, B., Bailey, C. J., O'Harte, F. P. M., & Flatt, P. R. (2004) · Biological Chemistry · doi:10.1515/bc.2004.035 · Cited by 43
Self-citationO'Harte, F. P. M., Abdel‐Wahab, Y. H. A., Conlon, J. M., & Flatt, P. R. (1998) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(98)00084-1 · Cited by 42
Self-citationImplementation of GLP-1 Based Therapy of Type 2 Diabetes Mellitus Using DPP-IV Inhibitors
Holst, J. J. (2005) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-47920-6_33 · Cited by 39
GAULT, V. A., FLATT, P. R., BAILEY, C. J., HARRIOTT, P., GREER, B., MOONEY, M. H., & O'HARTE, F. P. M. (2002) · Biochemical Journal · doi:10.1042/bj20020319 · Cited by 39
Self-citationGault, V. A., Flatt, P. R., Harriott, P., Mooney, M., Bailey, C. J., & O'Harte, F. P. M. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1760133 · Cited by 39
Self-citationBurcelin, R., ROLLAND, E., Dolci, W., GERMAIN, S., CARREL, V., & Thorens, B. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08510.x · Cited by 37
O'Harte, F. P. M., Gray, A. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (1997) · Peptides · doi:10.1016/s0196-9781(97)00201-5 · Cited by 37
Self-citationThe Positive Charge of the Imidazole Side Chain of Histidine7 Is Crucial for GLP-1 Action.
HARETER, A., HOFFMANN, E., BODE, H.-P., GÖKE, B., & GÖKE, R. (1997) · Endocrine Journal · doi:10.1507/endocrj.44.701 · Cited by 37
Green, B., Gault, V., Mooney, M., Irwin, N., Bailey, C., Harriott, P., Greer, B., Flatt, P., & O'Harte, F. (2003) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0310529 · Cited by 36
Self-citationGreen, B., Mooney, M., Gault, V. A., Irwin, N., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2004) · Metabolism · doi:10.1016/j.metabol.2003.09.015 · Cited by 35
Self-citationGlucagon-like peptide-I-(7–37) suppresses hyperglycemia in rats
Hendrick, G. K., Gjinovci, A., Baxter, L. A., Mojsov, S., Wollheim, C. B., Habener, J. F., & Weir, G. C. (1993) · Metabolism · doi:10.1016/0026-0495(93)90163-i · Cited by 32
Doyle, M. E., Greig, N. H., Holloway, H. W., Betkey, J. A., Bernier, M., & Egan, J. M. (2001) · Endocrinology · doi:10.1210/endo.142.10.8410 · Cited by 31
Green, B., Gault, V. A., Irwin, N., Mooney, M. H., Bailey, C. J., Harriott, P., Greer, B., Flatt, P. R., & O'Harte, F. P. M. (2003) · Biological Chemistry · doi:10.1515/bc.2003.171 · Cited by 28
Self-citationO'Harte, F. P. M., Mooney, M., Kelly, C., McKillop, A. M., & Flatt, P. R. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00125-7 · Cited by 27
Self-citationNäslund, E. B., Skogar, S., Efendić, S., & Hellström, P. M. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00054-x · Cited by 25
Siegel, Scharf, Gallwitz, Mentlein, Morys‐Wortmann, Fölsch, & Schmidt (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00440.x · Cited by 24
Chou, J. Z., Place, G. D., Waters, D. G., Kirkwood, J. A., & Bowsher, R. R. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js9700560 · Cited by 19
Gault, V. A., O'Harte, F. P. M., Harriott, P., & Flatt, P. R. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00027-1 · Cited by 17
Self-citationJones, I. R., Owens, D. S., Luzio, S. D., & Tm, H. (1989) · Hormone and Metabolic Research · doi:10.1055/s-2007-1009141 · Cited by 15
Jc, B., & Pederson, R. (1970) · PubMed · Cited by 10
Glucagon-like peptide-1 and the entero-insular axis in obese hyperglycaemic (ob/ob)mice
Bailey, C. J., & Flatt, P. R. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90364-x · Cited by 8
Self-citation
Cited by
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Use of Alcalase in the production of bioactive peptides: A review
Tacias-Pascacio, V. G., Morellon-Sterling, R., Siar, E.-H., Tavano, O., Berenguer-Murcia, Á., & Fernandez-Lafuente, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.10.060 · Cited by 407
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 223
“Other antidiabetic actions of the incretin hormones are summarised in table 1 and detailed elsewhere.(4,7) Most noteworthy are the inhibition of glucagon secretion, induction of satiety, tendency for weight loss and the reduced rate of gastric emptying(20) associated with GLP-1.”
BackgroundSelf-citationIncretin-Based Therapies in Type 2 Diabetes Mellitus
Chia, C. W., & Egan, J. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2109 · Cited by 223
Harnedy, P. A., O’Keeffe, M. B., & FitzGerald, R. J. (2015) · Food Chemistry · doi:10.1016/j.foodchem.2014.09.083 · Cited by 201
Metadata
- Authors
- Green, B., Gault, V., O'Harte, F., & Flatt, P.
- Affiliations
- University of Ulster (GB)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-11-01
- Volume
- 10
- Issue
- 29
- Pages
- 3651-3662
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2118100404
- Cited by
- 111
- References
- 116
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 2 · 2014: 4 · 2013: 4 · 2012: 2
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, GLP-1 analogues, type 2 diabetes, incretins, insulin secretion, cyclic AMP, antidiabetic drugs, N-terminal modification, amino acid substitutions, antidiabetic activity
- MeSH terms
- Animals, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon, Humans, Hypoglycemic Agents, Peptide Fragments, Protein Precursors, Structure-Activity Relationship, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.